Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss ...

It was previously corrected to change the brokerage's name to Leerink Partners, not Jefferies, in paragraph 4) Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy ...